We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Sanofi Pipeline Woes Continue with FDA Rejection of Lemtrada sBLA
Sanofi Pipeline Woes Continue with FDA Rejection of Lemtrada sBLA
The FDA has rejected Sanofi’s plans for an expanded indication in relapsing multiple sclerosis for its drug Lemtrada, the second pipeline setback for the company since November.